Actavis and Durata Therapeutics, Inc., have entered into a definitive merger agreement under which a subsidiary of Actavis will purchase Durata for approximately $675 million. The acquisition of Durata immediately enhances Actavis’ infectious disease portfolio with the addition of Dalvance (dalbavancin) for injection, the first and only IV antibiotic for acute bacterial skin and skin structure infections (ABSSSI) with once-a-week dosing for two weeks. Dalvance was approved by the U.S. Food...